A new study by the American Association for the Study of Liver Diseases examined 2,350 patients prescribed hepatitis C cures during the first six months that the medications were available on the market. The study found 46 percent of Medicaid beneficiaries were denied coverage even after an appeal, as compared to approximately 10 percent of commercially insured patients and 5 percent of Medicare patients. The most common reasons for denial included insufficient information to assess medical need, lack of medical necessity, and use of alcohol or controlled substances. Read Politico’s synopsis here.
Last Updated on May 7, 2020 by Aimed Alliance
